Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines

Benedict Shi Xiang Lian¹, Angeline En Hui Yek¹, Hemalata Shuvas¹, Siti Fairus Abdul Rahman¹, Kalaivani Muniandy² and Nethia Mohana-Kumaran¹*

Abstract
Objective: There are number of studies which report that BCL-2 anti-apoptotic proteins (e.g. BCL-2, BCL-XL, and MCL-1) are highly expressed in cervical cancer tissues compared to the normal cervical epithelia. Despite these reports, targeting these proteins for cervical cancer treatment has not been explored extensively. BH3-mimetics that inhibit specific BCL-2 anti-apoptotic proteins may hold encouraging treatment outcomes for cervical cancer management. Hence, the aim of this pilot study is to investigate the sensitivity of cervical cancer cell lines to combination of two BH3-mimetics namely ABT-263 which selectively inhibits BCL-2, BCL-XL and BCL-w and A-1210477, a selective MCL-1 inhibitor.

Results: We report that combination of A-1210477 and ABT-263 exhibited synergistic effects on all cervical cancer cell lines tested. Drug sensitization studies revealed that A-1210477 sensitised the cervical cancer cell lines SiHa and CaSki to ABT-263 by 11- and fivefold, respectively. Sensitization also occurred in the opposite direction whereby ABT-263 sensitised SiHa and CaSki to A-1210477 by eightfold. This report shows that combination of ABT-263 and A-1210477 could be a potential treatment strategy for cervical cancer. Extensive drug mechanistic studies and drug sensitivity studies in physiological models are necessary to unleash the prospect of this combination for cervical cancer therapy.

Keywords: Cervical cancer, BH3-mimetic, ABT-263, A-1210477

Introduction
Cervical cancer is the third leading cause of cancer death in females in less developed nations [1]. The cure rate with existing treatment modalities is between 60 and 90% for women who are diagnosed early. Unfortunately, prognosis is poor for women who are diagnosed with advanced or recurrent cervical cancer. The 5-year survival for women with metastatic cancer is only 16.5% [2]. Thus far, cisplatin and paclitaxel remain as the most effective treatment and standard of care for cervical cancer management. Several targeted therapies were evaluated for treatment but only exhibited limited activity [1]. Bevacizumab a recombinant and humanized monoclonal antibody against vascular endothelial growth factor (VEGF) is the only targeted therapy which has demonstrated improved overall survival (3.7 months) when combined with chemotherapy in a phase III study [3].

The BCL-2 family proteins, divided into pro- and anti-apoptotic proteins are the regulators of the intrinsic apoptosis pathway [4]. The anti-apoptotic BCL-2 proteins are up-regulated in many cancers and hence have emerged as attractive targets for therapy especially with the development of BH3-mimetics namely ABT-263 which specifically targets these proteins [5, 6]. Numbers of studies have evaluated the expression of the anti-apoptotic proteins at different stages of cervical...
cancer using immunoblot, immunohistochemistry (IHC) and oligonucleotide microarray profiling. Using IHC, BCL-2 and tumour suppressor protein p53 was detected to co-express in biopsies of cervical lesions but not in the normal cervical epithelium [7]. Employing the same technique, expression levels of survivin (inhibitor of apoptosis), BCL-2 and KAI 1 (tumour metastases suppressor protein) were investigated in normal cervix, chronic cervicitis, cervical intraepithelial neoplasia (CIN) and cervical cancer. Expression levels of survivin and BCL-2 were higher in the cervical cancer tissues than in the normal cervix, chronic cervicitis, or CIN and vice versa for KAI 1. Collectively, high expression of survivin and BCL-2 and low expression of KAI 1 were reported to promote cervical cancer progression and metastasis [8]. Another study using IHC, demonstrated that expression of BCL-2 was the highest in the invasive squamous cell carcinoma cervical tissues compared to normal cervical epithelium and CIN tissues [9]. MCL-1 was found to be overexpressed in cervical cancer tissues compared to its normal counterpart and the overexpression was correlated with poor prognosis. In this study IHC and immunoblot yielded similar results, bolstering confidence in the findings [10]. Collectively, these studies suggest that the anti-apoptotic proteins are relevant targets for cervical cancer treatment.

ABT-263 binds with high affinity to anti-apoptotic proteins BCL-2 and BCL-XL and with lower affinity to BCL-w [5, 11]. ABT-263 has demonstrated impressive single agent activity against lymphoid malignancies and small cell lung cancer (SCLC). Phase I/II trials report that ABT-263 was either effective as a single agent [12] or in combination with other drugs in refractory chronic lymphocytic leukaemia (CLL) [13, 14]. In most solid tumours, it has become obvious that sensitivity to ABT-263 is determined by MCL-1, which the drug binds with very low affinity. Suppression of MCL-1 or induction of MCL-1 antagonist NOXA have shown to sensitize solid cancer cells to ABT-263 [15–17]. In the present study, we performed a preliminary study to investigate the sensitivity of three cervical cancer cell lines namely SiHa, CaSki, and C33A to combination of ABT-263 (Navitoclax, AbbVie Inc) [5], and MCL-1 selective inhibitor A-1210477 (AbbVie, Inc) [18] using 2-dimensional drug sensitivity assay.

Main text

Methods

Cell lines and culture

SiHa was maintained in DMEM medium supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS), 10 U/ml penicillin and 10 μg/ml streptomycin, 1% (v/v) HEPES, 1 mM sodium pyruvate and 2 mM l-glutamine. C33A was maintained in DMEM medium supplemented with 10% (v/v) heat-inactivated FBS, 10 U/ml penicillin and 10 μg/ml streptomycin, 2 mM l-glutamine and 4.5 g/l D-Glucose, and CaSki was maintained in RPMI medium supplemented with 10% heat-inactivated FBS, 10 U/ml penicillin and 10 μg/ml streptomycin. The human foreskin fibroblasts were maintained in DMEM medium supplemented with 20% (v/v) FBS, 1 mM sodium pyruvate and 2 mM l-glutamine. All cell culture reagents were purchased from Gibco; Thermo Fisher Scientific, Waltham, MA, USA. Cells were incubated in 37 °C, 5% CO2. Unnecessary passaging of cell lines was avoided; experiments were conducted within two passages of reference stocks.

Two-dimensional (2D) drug sensitivity assay

The 2D drug sensitivity assays were performed as described [19, 20]. Cells were seeded at 2500 cells per well in 96-well plates and left to attach for 6–7 h in a humidified incubator at 37 °C, 5% CO2. After attachment, cells were treated to a concentration series [0–32 μM] of single agent ABT-263 and A-1210477 and as combination along the long plate axis for 72 h. Similar drug concentrations of ABT-263 and A-1210477 as previously described by [18, 21] were used in this study. Sensitization to ABT-263 by A-1210477 was assessed by testing a fixed concentration of A-1210477 to increasing concentrations of ABT-263 and vice versa for 72 h. Cell proliferation was quantified by fluorescence of Sybr Green I nucleic acid stain (Molecular Probes, Thermo Fisher Scientific, Waltham, MA, USA) employing a plate reader with 485 nm excitation and 530 nm emission filters.

Statistical analyses

Comparisons of IC50 values of the combination with either single agent A-1210477 or ABT-263 were done by two-tailed paired T test using GraphPad Prism® version 7 software. The values of p-values are indicated as ***p ≤ 0.001 or ****p ≤ 0.0001.

Drug interaction analyses

Synergistic drug interaction was determined using the median effect principle as previously described by Chou and Talalay [22, 23]. The CompuSyn 1.0 software (CompuSyn Inc. NJ, USA) was employed to generate Fa-CI isobologram plots.

Results

Synergistic anti-proliferative effect of ABT-263 and A-1210477 in the cervical cancer cell lines

Despite number of studies reporting on high expression of the anti-apoptotic proteins in cervical cancer tissues, targeting these proteins for therapy received very
little attention. Here we conducted a preliminary study to investigate the sensitivity of three cervical cancer cell lines to BH3-mimetic ABT-263 which selectively inhibits BCL-2, BCL-XL and BCL-w and A-1210477, a selective MCL-1 inhibitor. The cells were tested to single agent activity of ABT-263 and A-1210477 and as combination. In order to determine that the drugs did have an effect on cell proliferation of normal cells, the drugs were tested on human foreskin fibroblasts (HFFs).

All three cervical cancer cell lines were resistant to single agent activity of ABT-263 (SiHa IC$_{50}$ 11.13 ± 0.48 µM; CaSki IC$_{50}$ 3.4 ± 0.13 µM; C33A IC$_{50}$ 11.77 ± 0.11 µM—Fig. 1a–c—closed diamond) and A-1210477 ((SiHa IC$_{50}$ 20.23 ± 0.55 µM; CaSki IC$_{50}$ 6.7 ± 0.04 µM; C33A IC$_{50}$ 11.97 ± 0.22 µM—Fig. 1a–c—closed triangle). Combination of ABT-263 and A-1210477 at 1:1 drug concentration ratio shifted the dose–response curve to the left exhibiting selective synergistic anti-proliferative effects in all three cell lines (SiHa IC$_{50}$ 3.07 ± 0.11 µM; CaSki IC$_{50}$ 6.7 ± 0.04 µM; C33A IC$_{50}$ 3.11 ± 0.06 µM—Fig. 1a–c—closed circle). The IC$_{50}$ of the drug combination in the HFFs was 8.1 ± 0.6 µM—Additional file 1—closed circle). The IC$_{50}$ concentration obtained for the combination in the HFFs were higher compared to the cervical cancer cell lines (Fig. 1a–c—closed circle) indicating that inhibition of cell proliferation in cervical cancer cell lines with combination of ABT-263 and A-1210477 could be achieved at lower drug concentrations without employing doses that could harm non-cancerous cells.

**Sensitization of cervical cancer cell lines SiHa and CaSki to ABT-263 by A-1210477 and vice versa**

Next, we investigated the sensitization effect of one drug by another in the SiHa and CaSki cells. We first tested the sensitization effect of ABT-263 by A-1210477 by adding a fix concentration of 4 µM of A-1210477 to increasing doses of ABT-263. SiHa and CaSki were resistant to single agent activity of ABT-263 (SiHa IC$_{50}$ 10.12 ± 0.34 µM; CaSki IC$_{50}$ 3.4 ± 0.13 µM—Fig. 2a, b—closed diamond). The presence of A-1210477 shifted the dose–response curve to the left, displaying the ability of A-1210477 to potentiate SiHa and CaSki to ABT-263 (SiHa IC$_{50}$ 2 ± 0.15 µM; CaSki IC$_{50}$ 0.3 ± 0.0013 µM—Fig. 2a, b—closed triangle) by 5- and 11-fold, respectively (Table 1). Sensitization was also studied in the opposite direction by adding a fix dose of...
ABT-263 (4 μM ABT-263 for SiHa and 2 μM ABT-263 for CaSki) to escalating doses of A-1210477. Both cells were resistant to single agent activity of A-1210477 (SiHa IC₅₀ 19.86 ± 0.53 μM; CaSki IC₅₀ 7.6 ± 0.11 μM—Fig. 2c, d—closed triangle). Combination with ABT-263 sensitized both cell lines to A-1210477 (SiHa IC₅₀: 2.58 ± 0.2 μM; CaSki IC₅₀ 0.9 ± 0.13 μM—Fig. 2c, d—closed diamond) by eightfold (Table 1). Combination index (CI) values for all combinations tested are shown in Table 1. Drug combination was synergistic at CI value of less than 1 (Additional file 2).

Taken together our data demonstrated that the drug combination synergistic anti-proliferative effects could be explained by the ability of both drugs to sensitize each other. Hence, ABT-263 and A-1210477 may be effective sensitizers at physiologically attainable doses.

**Table 1 Sensitization of cervical cell lines SiHa and CaSki to ABT-263 by A-1210477 and vice versa**

|          | SiHa                        | CaSki                      |
|----------|-----------------------------|----------------------------|
| A-1210477, μM | ABT-263 IC₅₀ (μM), fold sensitization by A-1210477 | ABT-263 IC₅₀ (μM), fold sensitization by A-1210477 |
| 0        | 10.11 ± 0.34                | 3.4 ± 0.13                 |
| 4        | 2 ± 0.15                    | 5.1***                     |
|          | A-1210477 IC₅₀ (μM), fold sensitization by ABT-263 | A-1210477 IC₅₀ (μM), fold sensitization by ABT-263 |
| 0        | 19.85 ± 0.53                | 7.6 ± 0.11                 |
| 2        | 0.9 ± 0.13                  | 8.4****                    |
| 4        | 2.58 ± 0.2                  | 7.7***                     |

The IC₅₀ values are doses of drug 1 (bolditalics) that kill 50% of the cells surviving the shown doses of drug 2 (italics). Fold sensitization IC₅₀ drug 1/IC₅₀ drug 2. Errors are SEM, n = 4

Statistically significant differences with the IC₅₀ of drug 1 (bolditalics) are shown as ***p ≤ 0.001 or ****p ≤ 0.0001 determined by two-tailed paired T test. Where the IC₅₀ was not calculable, the lower bound was employed

ABT-263 (4 μM ABT-263 for SiHa and 2 μM ABT-263 for CaSki) to escalating doses of A-1210477. Both cells were resistant to single agent activity of A-1210477 (SiHa IC₅₀ 19.86 ± 0.53 μM; CaSki IC₅₀ 7.6 ± 0.11 μM—Fig. 2c, d—closed triangle). Combination with ABT-263 sensitized both cell lines to A-1210477 (SiHa IC₅₀: 2.58 ± 0.2 μM; CaSki IC₅₀ 0.9 ± 0.13 μM—Fig. 2c, d—closed diamond) by eightfold (Table 1). Combination index (CI) values for all combinations tested are shown in Table 1. Drug combination was synergistic at CI value of less than 1 (Additional file 2).

Taken together our data demonstrated that the drug combination synergistic anti-proliferative effects could be explained by the ability of both drugs to sensitize each other. Hence, ABT-263 and A-1210477 may be effective sensitizers at physiologically attainable doses.
Discussion

Neutralisation of MCL-1 is required for enhanced anti-cancer efficacy of ABT-263. Hence, tumours that are normally unresponsive to ABT-263 may become amenable to treatment when combined with drugs which either repress MCL-1 or induce MCL-1 antagonist NOXA [21]. In our preliminary study, we aim to investigate the sensitivity of cervical cancer cell lines to ABT-263 when combined with MCL-1 selective inhibitor A-1210477. Our findings showed that compared to single agent treatment, combination of ABT-263 and A-1210477 caused a synergistic anti-proliferative effect in all three cell lines tested. The results obtained were in accordance with other studies [17, 24–27].

In order to fully unravel the potential of combination of ABT-263 with its partner drug, we tested the sensitization of the cervical cancer cell lines to ABT-263 by A-1210477 and vice versa. In our hands, ABT-263 sensitized cervical cancer cell lines SiHa and CaSki to A-1210477 and vice versa demonstrating that both drugs can augment the activity of each other and restore the apoptotic potential in tumour cells. This was in agreement with other studies which reported that ABT-263 sensitized the effect of docetaxel in SKOV3 ovarian cancer xenograft model and erlotinib in the NCI-H1650 NSCLC xenograft model [28]. Another study reported that ABT-263 enhanced the activity of etoposide and Bortezomib in vivo [29].

A-1210477, similar to our findings, sensitized a number of cell lines from different cancer types namely BxPC-3 pancreas adenocarcinoma line, H23-lung carcinoma line, EJ-1 gastric carcinoma line and OPM-2 multiple myeloma line to ABT-263 in vitro [18]. The sensitization effect of A-1210477 was also obvious in studies which used breast cancer [30] and non-Hodgkin's lymphoma cell lines [31]. However, A-1210477 although highly specific for MCL-1, its ability to bind to serum proteins may limit its bioavailability and this could lead to drug resistance in preclinical models and patients as sufficient amount may not reach the tumour site.

Taken together our data demonstrates that combination of ABT-263 and A-1210477 exhibited synergistic effects in all cervical cancer cell lines tested and both drugs have the ability to enhance the activity of each other at physiologically attainable concentrations. Combination of these drugs could be a potential therapy option to combat cervical cancer but further studies are necessary to fully unleash the prospect of this duo.

Limitations

Sensitivity of the cervical cancer cell lines to combination of ABT-263 and A-1210477 were performed in the 2D cell culture model. The 2D model is high-throughput and economical but it lacks the microenvironment that tumours encounter in vivo [32, 33]. Given that A-1210477 may demonstrate poor bioavailability in vivo, future studies in three-dimensional (3D) spheroid models, in vivo models and later in clinical trials should test combination of orally bioavailable ABT-263 with next generation MCL-1 inhibitors with improved bioavailability properties [34]. Future work should also investigate the expression of the BCL-2 proteins and caspases before and after treatment so that a mechanism for induction of apoptosis in cervical cancer cell lines by the drug combination could be established.

Additional files

**Additional file 1.** Anti-proliferative effects of ABT-263 and A-1210477 in human foreskin fibroblasts at 1:1 drug concentration ratios. This data shows the effect of the BH3 mimetic drug combination on cell viability of a non-cancerous cell line.

**Additional file 2.** Synergistic drug effects of ABT-263 and A-1210477 in the SiHa and CaSki cervical cancer cell lines. This data shows the drug combination interaction effects in two cervical cancer cell lines.

Abbreviations

VEGF: vascular endothelial growth factor; IHC: immunohistochemistry; CIN: cervical intraepithelial neoplasia; SCLC: small cell lung cancer; CLL: chronic lymphotoytic leukaemia; 2D: 2-dimensional; HFF: human foreskin fibroblasts; CI: combination index; 3D: 3-dimensional.

Authors' contributions

NM-K designed the experiments and wrote the manuscript. BSXL, AEHA, HS, SFAR, and KM performed the experiments, analysed, and interpreted the data. NM-K prepared the figures and tables. SFAR corrected and proofread the manuscript. All authors read and approved the final manuscript.

Author details

1 School of Biological Sciences, Universiti Sains Malaysia, 11800 Gelugor, Penang, Malaysia. 2 Institute for Molecular Medicine (INFORMM), Universiti Sains Malaysia, 11800 Gelugor, Penang, Malaysia.

Acknowledgements

We would like to thank AbbVie Inc for providing us with ABT-263 and A-1210477. We thank Prof. Dr. Cheong Sok Ching from Cancer Research Malaysia for providing us with the human foreskin fibroblasts and Prof. Dr. Nikolas Haass (University of Queensland, Australia), Assoc. Prof. Dr. Nigel McMillan (University of Griffith, Australia), and Assoc. Prof. Dr. Venugopal Balakrishnan (INFORMM, USM) for providing us with the cervical cancer cell lines.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analysed during this study are included in this published article (and its additional files).
Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
B.S.X. Lian and K. Muniandy are Universiti Sains Malaysia Fellowship recipients. This work was funded by the Fundamental Research Grant Scheme, Ministry of Higher Education Malaysia (203/PBIOLOGI/6711355 and 203/PBIOLOGI/6711551), Universiti Sains Malaysia Short-Term Grant (304/PBIOLOGI/6313312), and MAKNA Cancer Research Award 2015, National Cancer Council, Malaysia (304/PBIOLOGI/650828/M121).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 19 December 2017   Accepted: 20 March 2018
Published online: 27 March 2018

References
1. Fuentes A, Garcia AA. Advances in cervical cancer prevention and management of persistent, recurrent, and metastatic disease. 2016 update. Am J Hematol Oncol. 2016;12:6–17.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al. SEER cancer statistics review, 1975–2012. Bethesda: National Cancer Institute; 2015.
3. Tewari KS, Sill MW, Long HJ 3rd, Pensom RT, Huang H, Ramondetta LM, Landrum LM, Dakin A, Reid TJ, Leitao MM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–43.
4. Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27–36.
5. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8.
6. Reed JC. Bcl-2 on the brink of breakthroughs in cancer treatment. Cell Death Differ. 2018;25:3–6.
7. Grace VM, Shalini JV, Lekha TT, Devaraj SN, Devaraj H. Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2003;91:51–8.
8. Zhou XL, Wang M. Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis. Genet Mol Res. 2015;14:17059–67.
9. Astudillo H, Lopez T, Castillo S, Gariglio P, Benitez L, Pinski B, Bcl-2, PCNA expression, and apoptotic rates during cervical tumorigenesis. Ann N Y Acad Sci. 2003;1010:771–4.
10. Zhang T, Zhao C, Luo L, Zhao H, Cheng J, Xu F. The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol. 2012;29:1985–91.
11. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Auger DJ, Belli BA, Brunko M, Deckwer TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:657–81.
12. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488–96.
13. Kipps TJ, Wierda WG, Jones JA, Svinin LJ, Yang J, Cui Y, Busman T, Krivosikh A, Enschede S, Hummrichhouse R. Navitoclax (ABT-263) plus fludarabine/cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR): a phase 1 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Blood 2010;116:2455.
14. Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dynagi IS, Yalamanchili S, Chai A, Sahasranaman S, Punnese E, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:2826–33.
15. Airaiu K, Prouzet-Mauleon V, Rousseau B, Pigneux A, Jeanneteau M, Giraudon M, Allou K, Dubus P, Bellort F, Mahon FX. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells. Oncotarget. 2016;7:845–59.
16. Jane EP, Premkumar DR, Cavaleri JM, Sutera PA, Rajasekar T, Pollack IF. Dinaciclib, a cyclin-dependent kinase inhibitor promotes proteasomal degradation of McI-1 and enhances ABT-737-mediated cell death in malignant human glioma cell lines. J Pharmacol Exp Ther. 2016;356:354–65.
17. Nakajima W, Sharma K, Hicks MA, Le N, Brown R, Krystal GW, Harada H. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Cancer Biol Ther. 2016;17:27–33.
18. Leversond J, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015;6:e1590.
19. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res. 2002;62:2294–9.
20. McGowan EM, Alling N, Jackson EA, Yagoubi D, Haas NK, Allen JD, Martinellino-Wilks R. Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay. PLoS ONE. 2011;6:e20623.
21. Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK, Allen JD. Modulation of NOXA and MCL-1 as a strategy for sensitizing human melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res. 2012;18:783–95.
22. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergy and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–81.
23. Chou TC, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.
24. Huang S, Okamoto K, Sincrope FA. Carfilzomib synergistically enhances ABT-263-induced apoptosis due to NOXA induction in KRAS wild type and mutant colorectal cancer cell lines. Cancer Res. 2014;74:337.
25. Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caballero M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubct CT, Ham J, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci USA. 2015;112:E288–96.
26. Lam LT, Zhang H, Xue J, Leversond J, Bhatnaha A. Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines. Cancer Cell Int. 2015;15:55.
27. Muhlenberg T, Grunewald S, Treckmann J, Podleska L, Schuler M, Fletcher JA, Bauer S. Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor. PLoS ONE. 2015;10:e0120531.
28. Chen J, Jin S, Abraham Y, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, et al. The Bcl-2/Bcl-XL/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011;10:2340–9.
29. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, Xiao Y, Tse C, Frost DJ, Fesik SW, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66:869–80.
30. Xiao Y, Nimmer P, Sheppard GS, Brunko M, Hessler P, Lu X, Roberts-Rapp L, Pappano WN, Elmore SW, Souers AJ, et al. MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther. 2015;14:1837–47.
31. Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, Leversond JD. Loss in MCL-1 function sensitizes non-Hodgkin's
lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368.
32. Beaumont KA, Mohana-Kumaran N, Haass NK. Modeling melanoma in vitro and in vivo. Healthcare (Basel). 2013;2:27–46.
33. Siva Sankar P, Che Mat MF, Muniandy K, Lian BSX, Phang SL, Hoe SL, Khoo AS, Mohana-Kumaran N. Modeling nasopharyngeal carcinoma in three dimensions. Oncol Lett. 2017;13:2034–44.

34. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Brazat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477–82.